Paper Details

  1. Home
  2. Paper Details

Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.

Author: AkagiSatoshi, EjiriKentaro, ItoHiroshi, KurodaKazuhiro, NakamuraKazufumi, SarashinaToshihiro

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article explores the transition from phosphodiesterase type 5 inhibitors (PDE5i) to riociguat, both drugs used to treat pulmonary arterial hypertension (PAH), in patients who do not respond to combination therapy or experience side effects. It highlights the importance of washout periods to minimize haemodynamic instability during the transition.
Paper Details　
Original Abstract of the Article :
Transition to pulmonary arterial hypertension (PAH)-specific drugs is considered in patients with PAH and chronic thromboembolic pulmonary hypertension who do not respond to combination therapy or who experience side effects to the combination drugs. Riociguat directly stimulates soluble guanylate c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.hlc.2019.01.013

データ提供：米国国立医学図書館（NLM）

Transitioning PAH Treatment: A Smooth Journey Across the Desert

Pulmonary arterial hypertension (PAH) is a complex and potentially debilitating condition, often requiring careful management. This study explores the transition of PAH patients from phosphodiesterase type 5 inhibitors (PDE5i), a common treatment, to riociguat, a newer drug that directly stimulates soluble guanylate cyclase. The research investigates the effectiveness of this transition without a washout period, examining the potential for haemodynamic instability during the switch. The study offers insights into the safety and efficacy of this transition strategy, aiming to optimize PAH treatment for patients.

Navigating the Desert of PAH Treatment: A New Oasis for Patients

The study suggests that transitioning from PDE5i to riociguat without a washout period can be a safe and effective option for PAH patients. The research opens new possibilities for managing PAH, potentially improving treatment outcomes for patients. This research is a valuable step forward in understanding the complexities of PAH treatment and developing more effective and personalized approaches.

Living with PAH: Finding Stability in the Desert

PAH can be a challenging journey, requiring ongoing attention and management. This study provides valuable insights into transitioning PAH treatment, potentially improving the stability and effectiveness of care. It serves as a reminder that progress continues in this field, offering hope for a brighter future for PAH patients.

Dr. Camel's Conclusion

The desert of PAH treatment is a complex and ever-changing landscape. This study explores the potential of transitioning patients from PDE5i to riociguat without a washout period, offering a potentially safer and more effective approach. This research underscores the importance of continuous exploration and innovation in finding the best ways to manage this challenging condition.

Date :
  1. Date Completed 2020-11-26
  2. Date Revised 2020-11-26
Further Info :

Pubmed ID

30773322

DOI: Digital Object Identifier

10.1016/j.hlc.2019.01.013

Related Literature

Article Analysis
・Side Effects of riociguat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.